Portfoliotracker

Nuvectis Pharma, Inc.

NVCT · NASDAQCM · Healthcare Biotechnology 27/100 E

19,11 $
▼ −1,13 (−5,58 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:32
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score27 / 100 Market cap563 mil. $ P/E– Forward P/E-19,9 P/S– P/B4,4 EV/EBITDA– Dividend yield– FCF yield-3,46 % EPS-2,00 $ Net margin0,0 % Return on equity-67,0 % Beta-0,21 Debt / equity–
52-week range 5,77 to 29,28
3-month average volume0,2 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Employees
19
Country
United States
Fiscal year end
31. 12.
Data since
4. 2. 2022

Explore further

Similar companies IMMXTRDAFHTX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account